Overview

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Status:
Active, not recruiting

Trial end date:
2021-12-08

Target enrollment:

Participant gender:

Summary

This is an open-label, non-randomized, multicenter, Phase 2 study evaluating the efficacy and safety of ABT-199 in approximately 120 subjects with relapsed or refractory CLL after B-cell receptor signaling pathway inhibitors (BCR PI) treatment.

Phase:

Phase 2

Details

Lead Sponsor:

AbbVie

Collaborators:

Genentech/Roche
Roche-Genentech

Treatments:

Idelalisib
Receptors, Antigen, B-Cell
Venetoclax